US2021317207A1PendingUtilityA1
Anti-human vista antibodies and use thereof
Est. expiryApr 15, 2036(~9.8 yrs left)· nominal 20-yr term from priority
Inventors:Randolph J. NoelleSabrina DelongMichael MolloyCatherine CarriereJay RothsteinIsabelle Lemercier
A61K 38/16A61K 39/00C07K 14/705C07K 16/42C07K 16/46A61K 39/395C07K 2317/24C07K 2317/53C07K 2317/52C07K 2317/73C07K 2317/522A61P 31/00A61P 35/02A61P 35/00C07K 2317/76A61P 37/06A61P 1/00C07K 2317/75A61P 11/00C07K 16/2827A61P 17/06C07K 2317/92A61P 19/02A61P 17/14C07K 16/2803C07K 2317/34C07K 2317/31A61P 13/02C07K 2317/33A61P 31/14A61P 37/02C07K 2317/74A61P 1/16A61P 43/00C07K 16/2896A61P 13/12C07K 2317/565A61K 38/17A61P 25/00A61P 29/00A61K 2039/505C07K 2317/21A61P 17/00A61P 9/10A61K 39/3955A61P 37/08A61K 45/06A61P 31/20A61P 39/02Y02A50/30
74
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The invention provides agonistic anti-human VISTA antibodies and antibody fragments. These agonist antibodies and antibody fragments may be used to potentiate or enhance or mimic VISTA's suppressive effects on T cell immunity and thereby suppress T cell immunity. These agonist antibodies and antibody fragments are especially useful in the treatment of autoimmunity, allergy, inflammatory conditions, GVHD, sepsis and transplant recipients. Screening assays for identifying these agonists are also provided.
Claims
exact text as granted — not AI-modified1 . A method of treating or preventing an autoimmune, allergic or inflammatory condition comprising administering to a patient in need thereof a therapeutically or prophylactically effective amount of an isolated antibody or antibody fragment thereof comprising an antigen binding region that specifically binds to human V-domain Ig Suppressor of T cell Activation (human VISTA), wherein the antibody or antibody fragment agonizes or promotes one or more of the effects of VISTA on immunity.
2 - 119 . (canceled)Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.